Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.
Where this comes from
- Record sourced from PubMed, PMID 22323827.
- Also identified by DOI 10.1126/scitranslmed.3003728.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been validated as targeted therapeutics. Unfortunately, as with other oncogene-driven tumors, therapeutic resistance invariably develops. In Science Translational Medicine, two recent studies provide new insight into mechanisms of resistance to ALK tyrosine kinase inhibitors and possible strategies to overcome this resistance.
Medical subject headings
- Lung Neoplasms
- Protein Kinase Inhibitors
- Pyrazoles
- Pyridines
- Receptor Protein-Tyrosine Kinases